These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 31039818)

  • 1. Transcriptome signatures associated with meningioma progression.
    Viaene AN; Zhang B; Martinez-Lage M; Xiang C; Tosi U; Thawani JP; Gungor B; Zhu Y; Roccograndi L; Zhang L; Bailey RL; Storm PB; O'Rourke DM; Resnick AC; Grady MS; Dahmane N
    Acta Neuropathol Commun; 2019 Apr; 7(1):67. PubMed ID: 31039818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.
    Sahm F; Schrimpf D; Stichel D; Jones DTW; Hielscher T; Schefzyk S; Okonechnikov K; Koelsche C; Reuss DE; Capper D; Sturm D; Wirsching HG; Berghoff AS; Baumgarten P; Kratz A; Huang K; Wefers AK; Hovestadt V; Sill M; Ellis HP; Kurian KM; Okuducu AF; Jungk C; Drueschler K; Schick M; Bewerunge-Hudler M; Mawrin C; Seiz-Rosenhagen M; Ketter R; Simon M; Westphal M; Lamszus K; Becker A; Koch A; Schittenhelm J; Rushing EJ; Collins VP; Brehmer S; Chavez L; Platten M; Hänggi D; Unterberg A; Paulus W; Wick W; Pfister SM; Mittelbronn M; Preusser M; Herold-Mende C; Weller M; von Deimling A
    Lancet Oncol; 2017 May; 18(5):682-694. PubMed ID: 28314689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meningioma progression in mice triggered by Nf2 and Cdkn2ab inactivation.
    Peyre M; Stemmer-Rachamimov A; Clermont-Taranchon E; Quentin S; El-Taraya N; Walczak C; Volk A; Niwa-Kawakita M; Karboul N; Giovannini M; Kalamarides M
    Oncogene; 2013 Sep; 32(36):4264-72. PubMed ID: 23045274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignant progression to anaplastic meningioma: Neuropathology, molecular pathology, and experimental models.
    Cimino PJ
    Exp Mol Pathol; 2015 Oct; 99(2):354-9. PubMed ID: 26302177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinicopathological analysis of receptor tyrosine kinases in meningiomas: the expression of VEGFR-2 in meningioma was associated with a higher WHO grade and shorter progression-free survival.
    Nakada S; Sasagawa Y; Tachibana O; Iizuka H; Kurose N; Shioya A; Guo X; Yamada S; Nojima T
    Brain Tumor Pathol; 2019 Jan; 36(1):7-13. PubMed ID: 30519894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignant progression in meningioma: documentation of a series and analysis of cytogenetic findings.
    Al-Mefty O; Kadri PA; Pravdenkova S; Sawyer JR; Stangeby C; Husain M
    J Neurosurg; 2004 Aug; 101(2):210-8. PubMed ID: 15309910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade.
    Schmidt M; Mock A; Jungk C; Sahm F; Ull AT; Warta R; Lamszus K; Gousias K; Ketter R; Roesch S; Rapp C; Schefzyk S; Urbschat S; Lahrmann B; Kessler AF; Löhr M; Senft C; Grabe N; Reuss D; Beckhove P; Westphal M; von Deimling A; Unterberg A; Simon M; Herold-Mende C
    Oncotarget; 2016 Mar; 7(12):14551-68. PubMed ID: 26894859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microarray Expression Data Identify DCC as a Candidate Gene for Early Meningioma Progression.
    Schulten HJ; Hussein D; Al-Adwani F; Karim S; Al-Maghrabi J; Al-Sharif M; Jamal A; Al-Ghamdi F; Baeesa SS; Bangash M; Chaudhary A; Al-Qahtani M
    PLoS One; 2016; 11(4):e0153681. PubMed ID: 27096627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TERT promoter mutations in primary and secondary WHO grade III meningioma.
    Maier AD; Stenman A; Svahn F; Mirian C; Bartek J; Juhler M; Zedenius J; Broholm H; Mathiesen T
    Brain Pathol; 2021 Jan; 31(1):61-69. PubMed ID: 32805769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.
    Dewan R; Pemov A; Dutra AS; Pak ED; Edwards NA; Ray-Chaudhury A; Hansen NF; Chandrasekharappa SC; Mullikin JC; Asthagiri AR; ; Heiss JD; Stewart DR; Germanwala AV
    BMC Cancer; 2017 Feb; 17(1):127. PubMed ID: 28193203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-cell RNA sequencing identifies macrophage signatures correlated with clinical features and tumour microenvironment in meningiomas.
    Zhang X
    IET Syst Biol; 2023 Oct; 17(5):259-270. PubMed ID: 37515398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and gene doses changes of the p53-regulator PPM1D in meningiomas: a role in meningioma progression?
    Fukami S; Riemenschneider MJ; Kohno M; Steiger HJ
    Brain Tumor Pathol; 2016 Jul; 33(3):191-9. PubMed ID: 26942600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures.
    Collord G; Tarpey P; Kurbatova N; Martincorena I; Moran S; Castro M; Nagy T; Bignell G; Maura F; Young MD; Berna J; Tubio JMC; McMurran CE; Young AMH; Sanders M; Noorani I; Price SJ; Watts C; Leipnitz E; Kirsch M; Schackert G; Pearson D; Devadass A; Ram Z; Collins VP; Allinson K; Jenkinson MD; Zakaria R; Syed K; Hanemann CO; Dunn J; McDermott MW; Kirollos RW; Vassiliou GS; Esteller M; Behjati S; Brazma A; Santarius T; McDermott U
    Sci Rep; 2018 Sep; 8(1):13537. PubMed ID: 30202034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Characterization of Higher-Grade Meningiomas: A Histopathological Score to Predict Progression and Outcome.
    Bertero L; Dalla Dea G; Osella-Abate S; Botta C; Castellano I; Morra I; Pollo B; Calatozzolo C; Patriarca S; Mantovani C; Rudà R; Tardivo V; Zenga F; Garbossa D; Papotti M; Soffietti R; Ricardi U; Cassoni P
    J Neuropathol Exp Neurol; 2019 Mar; 78(3):248-256. PubMed ID: 30689922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathology and genetics of meningiomas.
    Alahmadi H; Croul SE
    Semin Diagn Pathol; 2011 Nov; 28(4):314-24. PubMed ID: 22195409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic alterations associated with progression and recurrence in meningiomas.
    Pérez-Magán E; Campos-Martín Y; Mur P; Fiaño C; Ribalta T; García JF; Rey JA; Rodríguez de Lope A; Mollejo M; Meléndez B
    J Neuropathol Exp Neurol; 2012 Oct; 71(10):882-93. PubMed ID: 22964784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma.
    Lusis EA; Watson MA; Chicoine MR; Lyman M; Roerig P; Reifenberger G; Gutmann DH; Perry A
    Cancer Res; 2005 Aug; 65(16):7121-6. PubMed ID: 16103061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathodiagnostic parameters and evaluation of O⁶- methyl guanine methyl transferase gene promoter methylation in meningiomas.
    Jabini R; Moradi A; Afsharnezhad S; Ayatollahi H; Behravan J; Raziee HR; Mosaffa F
    Gene; 2014 Apr; 538(2):348-53. PubMed ID: 24398011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NF2 mutation status and tumor mutational burden correlate with immune cell infiltration in meningiomas.
    Rutland JW; Gill CM; Loewenstern J; Arib H; Pain M; Umphlett M; Kinoshita Y; McBride RB; Bederson J; Donovan M; Sebra R; Shrivastava RK; Fowkes M
    Cancer Immunol Immunother; 2021 Jan; 70(1):169-176. PubMed ID: 32661686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histological classification and molecular genetics of meningiomas.
    Riemenschneider MJ; Perry A; Reifenberger G
    Lancet Neurol; 2006 Dec; 5(12):1045-54. PubMed ID: 17110285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.